1. A REVOLUTION IN BREAST CANCER DETECTION

2. ANGELO FERRARIO – Quanta System SpA- ITALY A. Oraewsky – Fairway Medical Technology -TX- USA Laser-Optoacoustic medical Imaging System LOIS

3. BASICS OF OPTO-ACOUSTICS 3

4. OPTO-ACOUSTICS REPLICATES DISTRIBUTION OF ABSORBED OPTICAL ENERGY 4

5. TISSUE SPECTRAL SENSITIVITIES*  Oxygenated and deoxygenated hemoglobin in tissue absorb light differently at 755 nm and 1,064 nm 5 * Compilation of optical spectra by Steven Jacques and Scott Prahl, Oregon Medical Laser Center: http://omlc.ogi.edu/spectra/

6. Max Sensitivity of OA Detection p N - noise pressure ( SNR =1 )  - thermoacoustic efficiency µ a - tumor absorption coefficient r z F0F0 2a2a

7. Signal Recovery from SNR<<1

8. LOIS Electronics (signal acquisition, processing and reconstruction) 32 PVDF transducers 32 preamplifiers 32 signal amplifiers 32 ADCs FPGA Ethernet To computer 4 independent boards: Sampling rate Synchro

9. 3D Tomo System for Preclinical Research 64 Channel piezo-composite elements with 3.1 MHz center frequency 65 mm focal length Movement control in XYZ and 360 0 Rotation Orthogonal illumination using randomized fiber bundle Custom made data acquisition and analog amplifier: – Variable gain between 0 - 80 dB – 60dB Time-Gain control available – Up to 256 channels Custom made DAQ: – Max sampling rate of 40 MHz – FPGA for signal processing and system control Spherical BP reconstruction using complete data set with weighting that compensates for density of virtual transducers

10. 10 Vasculate and Microvasculate is the Basis for Imaging §Angiogenesis Mouse Organs

11. 11 Vasculate and Microvasculate is the Basis for Imaging §Angiogenesis Mouse Vasculation

12. 12 Seno’s is the first device for breast care with functional and morphological information co-registered and correlated  Indicates malignant state of tissue noninvasively  Diagnoses women with dense breast tissue and implants  Utilizes skills of technicians trained in ultrasound imaging and requires no special training 12 BENEFITS OF OPTO-ACOUSTIC IMAGING

13. BASICS OF OPTO-ACOUSTICS 13

14. Breast Cancer Patient Scanned by IMAGIO 1064 nm 755 nm US+1064 nm US+755 nm 14

15. 15 UNDERLYING MAGIC  First Dual Modality (Ultrasound & functional information combined) for breast care  Portable, cost effective (not $ millions)  No invasive dyes or radioisotopes  No special buildings to house equipment  Safety w/real-time diagnosis for patients  Reduction of unnecessary health procedures (callbacks & biopsies)

16. 16 BREAST CANCER IS THE #1 KILLER OF WOMEN  Mammograms find tumors; they can’t determine if the tumors are cancerous  85% of biopsies determine tumors are benign  Seno’s technology will eliminate 82% of false positives and 98% false negatives  This will save the healthcare system billions of dollars in “wasted” invasive procedures

17. 17 SENO’S GAME CHANGING TECHNOLOGY  Seno’s patented opto-acoustic imaging technology detects cancer earlier and cheaper than the competition  Seno’s technology detects tumors and can tell if they are cancerous by the density of angiogenesis and blood oxygen  Seno’s technology provides real-time diagnostic data and eliminates: Unnecessary biopsies, Injection of a contrast agent into women and Delays between detection and follow-up action

18. 18 THE BREAST CANCER DETECTION MARKET  Breast Cancer exams and treatment are an $8 billion market – $4.7 billion is for detection and follow-up exams (U.S.) – Seno’s segment for equipment purchase is $1.5 billion  Breast imaging is a growing global market  Seno’s technology can also be used in the early detection of other cancers – This is an additional $40 billion market opportunity

19. Diagnostic Mammogram Risks: Ionizing Radiation Ultrasound Risks: None fMRI Risks: Contrast Agents Seno Imagio™ Cost comparable to other functional modalities Risks: None Needle Core / Surgical Biopsy Screening Mammogram Risks: Ionizing Radiation Needle Core / Surgical Biopsy Risks: Infection, Bleeding, Pain, Healing, Anesthesia 19 IMPROVED CARE PATH FOR SUSPICIOUS LESIONS $800 $2,200

20. 20 Additional Literature on Optoacoustic Imaging A.A. Oraewsky A.A. Karabutov : “Time resolved detection of Optoacoustic Profiles for Measurement of Optical Energy Distribution in Tissues” - Handbook of optical biomedical diagnostics, V.V Tuchin, SPIE Press, Chapter 10, pp 585-646, 2002 A.A. Oraewsky A.A. Karabutov : “ Optoacoustic Tomography” - Biomedical Photonics Handbook, T. Vo-Dinh, CRC Press, pp 34/1-34/34, 2003 A.A. Oraewsky : “Optoacoustic Tomography of the Breast”, Chapter 33 in “Photoacoustic Imaging and spectroscopy” L.Wang, Taylor and Francis Group, New York, 2009 A.A. Oraewsky : “Gold and silver nanoparticles as contrast agents for optocoustic imaging” - Chapter 30 in “Photoacoustic imaging and spectroscopy”, L.Wang, Taylor and Francis Group, New York, 2009 S.A. Ermilov, T.KHamapirad, A.Conjusteau, R.LAcewell, K.Metha, T.Miller, M.H. Leonard, A.A.Oraewsky: Laser Optoacoustc Imaging System for Detection of Breast Cancer – J. Biomed Opt. 2009 – 14(2):024007 (1-14) P.Brecht. A.A.Oraewsky : Whole body three-dimensional optoacoustic tomography for a mouse, J.Biomed Opt. 2009 14(6), 1-7

21. 21 SENO’S PATENTS  Own core patent in medical opto-acoustics (OA)  Patent issued  Broad claims  Other entity's commercialization infringes  Core patent vetted  Fulbright & Jaworski for State of Texas investment in Seno  Greenberg Traurig – International law firm  License partner validates “Freedom to Operate”  Licensed patents  16 patents/applications worldwide  Concepts documented for future patents  Reviewing patents for in-licensing

22. A REVOLUTION IN BREAST CANCER DETECTION